Lysophospholipid growth factors in the initiation, progression, metastases, and management of ovarian cancer.
about
Convergence of multiple signaling cascades at glycogen synthase kinase 3: Edg receptor-mediated phosphorylation and inactivation by lysophosphatidic acid through a protein kinase C-dependent intracellular pathway.MAGI-3 regulates LPA-induced activation of Erk and RhoAOver-expression of lysophosphatidic acid receptor-2 in human invasive ductal carcinomaDecreased peritoneal ovarian cancer growth in mice lacking expression of lipid phosphate phosphohydrolase 1.Inhibition of PC cell-derived growth factor (PCDGF)/granulin-epithelin precursor (GEP) decreased cell proliferation and invasion through downregulation of cyclin D and CDK4 and inactivation of MMP-2Lysophosphatidic acid enhanced the angiogenic capability of human chondrocytes by regulating Gi/NF-kB-dependent angiogenic factor expressionReactive oxygen species mediate lysophosphatidic acid induced signaling in ovarian cancer cells.Differential levels of L-homocysteic acid and lysophosphatidylcholine (16:0) in sera of patients with ovarian cancerLPA5 is abundantly expressed by human mast cells and important for lysophosphatidic acid induced MIP-1β releaseActivation of NF-kappaB signaling by inhibitor of NF-kappaB kinase beta increases aggressiveness of ovarian cancer.Lysophosphatidic Acid Upregulates Laminin-332 Expression during A431 Cell Colony Dispersal.Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases.ATX-LPA receptor axis in inflammation and cancer.Transactivation of platelet-derived growth factor receptor alpha by the GTPase-deficient activated mutant of Galpha12.Identification of an intracellular receptor for lysophosphatidic acid (LPA): LPA is a transcellular PPARgamma agonist.Comparison of total plasma lysophosphatidic acid and serum CA-125 as a tumor marker in the diagnosis and follow-up of patients with epithelial ovarian cancerBioactive lipids, LPC and LPA, are novel prometastatic factors and their tissue levels increase in response to radio/chemotherapyThe dominance of the microenvironment in breast and ovarian cancer.Cytosolic phospholipase A2 as a molecular target for the radiosensitization of ovarian cancer.Activation of AMP-activated protein kinase is essential for lysophosphatidic acid-induced cell migration in ovarian cancer cells.Diverse mechanisms for activation of Wnt signalling in the ovarian tumour microenvironment.Regulation of mammalian physiology, development, and disease by the sphingosine 1-phosphate and lysophosphatidic acid receptors.Suppression of death receptor-mediated apoptosis by 1,25-dihydroxyvitamin D3 revealed by microarray analysis.SPARC inhibits LPA-mediated mesothelial-ovarian cancer cell crosstalk.Lysophosphatidic Acid disrupts junctional integrity and epithelial cohesion in ovarian cancer cells.LPA Stimulates the Phosphorylation of p130Cas via Gαi2 in Ovarian Cancer CellsLPA-mediated migration of ovarian cancer cells involves translocalization of Gαi2 to invadopodia and association with Src and β-pixThe role of LPA and YAP signaling in long-term migration of human ovarian cancer cells.Fluorogenic phospholipid substrate to detect lysophospholipase D/autotaxin activitySharpening the edges of understanding the structure/function of the LPA1 receptor: expression in cancer and mechanisms of regulation.Regulation of the LPA2 receptor signaling through the carboxyl-terminal tail-mediated protein-protein interactionsActivated epidermal growth factor receptor in ovarian cancer.Lysophosphatidic acid (LPA)-induced vasodilator-stimulated phosphoprotein mediates lamellipodia formation to initiate motility in PC-3 prostate cancer cellsFive markers useful for the distinction of canine mammary malignancy.Lysophosphatidyl choline modulates mechanosensitive L-type Ca2+ current in circular smooth muscle cells from human jejunum.Lysophosphatidic acid receptor 2 and Gi/Src pathway mediate cell motility through cyclooxygenase 2 expression in CAOV-3 ovarian cancer cells.Lysophosphatidic acid receptors determine tumorigenicity and aggressiveness of ovarian cancer cellsLysophosphatidic acid-3 receptor-mediated feed-forward production of lysophosphatidic acid: an initiator of nerve injury-induced neuropathic pain.Carbohydrate-containing molecules as potential biomarkers in colon cancer.Lysophosphatidic Acid Triggers Apoptosis in HeLa Cells through the Upregulation of Tumor Necrosis Factor Receptor Superfamily Member 21.
P2860
Q24537174-1E73B8AE-6959-40B6-A7DA-C9D13D80FD7EQ24680474-92C9E685-B2DA-4977-9B59-588CCA02D56CQ24796051-4885F5BA-9550-4604-9290-EE44081A802DQ30300375-0438B653-CF2C-4CE7-A6B0-58A1D21191A0Q33270736-FF5E8F22-E045-4D9A-B5C4-9404452441BDQ33689905-B7E0C554-3F84-4F64-AE63-8200570CA33EQ33713850-267D22E2-5006-439A-92F8-3463208A82DEQ33843741-7611EF47-6B46-4B4B-B04A-6ED8812579C3Q33862583-4DD5234F-5CBC-46FF-BC64-1524B3F8FAAFQ33862932-9EE3E90F-491D-407A-B4B9-7B5781BF6D6DQ34123656-45585F06-F929-4607-A9B5-2E80A163FE78Q34148745-E18951F6-EF80-42ED-8294-FEABA64947F9Q34199719-06A60E52-FCB0-481A-8A0C-7C979EA9D7BEQ34233512-0EFA84A4-7F57-4845-B5BD-A072B56112AAQ34466845-24F605D0-6A1C-445A-B776-35C0857E9822Q34517736-01C1E812-6106-4085-8972-589AC3E63B95Q34518525-D710A1DE-661C-4FC2-80F0-84034E722EACQ34654993-E11FEF6E-6A52-48D2-9C60-A1768DC6AA99Q34785252-AE765D07-85E8-4419-B322-2E3ABCDB95C1Q35085076-B0E0C4C2-4D17-4DAC-A20F-BE9573E23360Q35098085-D29B886F-7A61-4755-BE75-C20A33090F41Q35551835-8AD5B293-0B03-4D43-9BA3-204D34D1C3FFQ35646945-39F5F72C-6E64-49C4-9887-E37D0319F97EQ35647529-D69C96BC-FA17-49DE-8B1F-E76F88A86006Q35942558-51ED67F2-5DAA-47C6-89EF-4B0FDD7CD158Q36664973-FC3A70AD-3FF1-4CDE-AAA4-53312AE14BC6Q36767090-0CA39D36-9F76-4CE3-AA36-C7858F418031Q36847992-88BD6C34-D113-4E3E-97F0-E2173F6DCC72Q36861053-14C006C5-6728-4E60-8687-0C7A356A1DFBQ36932111-8AD528F5-CEAF-4FC0-89F9-AD10B42C627EQ36951961-18492576-D197-49D8-B3B0-A7AE6D3CC711Q36981918-50131107-B091-4BB1-8F8E-8EE750431E54Q37004375-7CD99373-CB71-4E89-9809-3CC25526FCEFQ37113240-58180636-D0BF-4466-8B62-29F1A4C82641Q37162450-4AE40BFB-49D1-454A-A7DC-B0BD3E43AB7EQ37185003-588D787B-CE5B-422A-9C78-53D4531ADD6BQ37289059-77D71288-9160-41C7-BEE2-CB1043DE0809Q37428175-D3D277B6-E162-4946-A9D0-78701DD9F887Q37686168-F48A6AA1-AE4B-4C7A-888A-63F213238881Q37700010-AA8400F5-9CF0-4146-A56D-6C3AF73CB778
P2860
Lysophospholipid growth factors in the initiation, progression, metastases, and management of ovarian cancer.
description
2000 nî lūn-bûn
@nan
2000 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Lysophospholipid growth factor ...... management of ovarian cancer.
@ast
Lysophospholipid growth factor ...... management of ovarian cancer.
@en
type
label
Lysophospholipid growth factor ...... management of ovarian cancer.
@ast
Lysophospholipid growth factor ...... management of ovarian cancer.
@en
prefLabel
Lysophospholipid growth factor ...... management of ovarian cancer.
@ast
Lysophospholipid growth factor ...... management of ovarian cancer.
@en
P2093
P1476
Lysophospholipid growth factor ...... d management of ovarian cancer
@en
P2093
D Gaudette
J R Erickson
J R Wiener
R Lapushin
P304
P356
10.1111/J.1749-6632.2000.TB06550.X
P407
P577
2000-04-01T00:00:00Z